Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study-Reference-Cited by-同舟云学术

Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study

Published:2001-05 Issue:2 Volume:81 Page:216-224
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Prince H.Miles,Rischin Danny,Quinn Michael,Allen David,Planner Robert,Neesham Deborah,Gates Priscilla,Davison Jill

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference63 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

2. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel;Bookman;J Clin Oncol,1998

3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J Clin Oncol,1997

4. Sequences of topotecan and cisplatin: a phase I, pharmacologic, and in vitro studies to examine sequence dependence;Rowinsky;J Clin Oncol,1996

5. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma;Raymond;Ann Oncol,1997

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study;Bone Marrow Transplantation;2006-02-27

2. Toxicity of the topoisomerase I inhibitors;Expert Opinion on Drug Safety;2005-01

3. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study;Gynecologic Oncology;2004-07

4. ZD9331 in combination with topotecan: phase I and II experience;Anti-Cancer Drugs;2003-05

5. Topoisomerase I interactive agents;Cancer Chemotherapy and Biological Response Modifiers Annual;2003